Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Open-Label Study of Moderna mRNA Vaccines for SARS-CoV-2 in Young Children
2024-000165-25Phase 3
- Sponsor
- Moderna Inc
- Start
- May 2024
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label trial of elasomeran + imelasomeran and mRNA-1273.815 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Moderna Inc. Primary endpoint: Solicited local and systemic adverse reactions.
02
Drugs
elasomeran + imelasomeranmRNA-1273.815
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2024-000165-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-000165-25.